An ongoing trial currently recruiting patients between the ages of 1 and 26 with HER2+ brain tumours, will test HER2 CAR T cell therapy, delivered via an indwelling catheter in the tumour resection cavity or the ventricles (NCT03500991). The gene discussed is ERBB2; the disease is neoplasm.